Larkfield swoops on Mont Albert office in $28m deal
Weâre sorry, this service is currently unavailable. Please try again later.
Dismiss
Save
Normal text size
Advertisement
Frank Hargraveâs Larkfield group has snapped up a three-level office building in Mont Albert for about $28 million.
Records show Larkfield has settled on the property at 3-7 Hamilton Street in Mont Albert this month, paying $27.85 million on a relatively soft yield of 6 per cent.
3-7 Hamilton Street in Mont Albert.
Credit:
The 3720 square metre building was extensively refurbished by the vendors, Ballarat developer and property lender MacCap.
Colliersâ Peter Bremner, Andrew Ryan, Hamish Burgess and Trent Hobart negotiated the deal.
Costs climb at forest recreation sites
helenair.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from helenair.com Daily Mail and Mail on Sunday newspapers.
Larkfield swoops on Mont Albert office in $28m deal
smh.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from smh.com.au Daily Mail and Mail on Sunday newspapers.
Larkfield swoops on Mont Albert office in $28m deal
brisbanetimes.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from brisbanetimes.com.au Daily Mail and Mail on Sunday newspapers.
What the bloody hell have I been saying for the last 6 years Martyn .
I have been saying for 6 years Pharmac is a law unto itself and BLATANT UNDER FUNDING OF MEDICINES IS THE CAUSE.
Now will you people in this group start listening to Me and PATIENT VOICE AOTEAROA.
Our pharmac model of one supplier single contract supply and drag the funding out till the cows come home is no LONGER FIT FOR THE 21st CENTURY.
WAKE THE HELL UP PEOPLE AS FAR AS HEALTHCARE IS CONCERNED WE ARE 3rd world.
Read this ;
Dear PVA members and followers.
I love that this forum is a great theatre for discussion and I’ve noted with interest some of the dialogue relating to the review of Pharmac. I wanted to take a second to look a little more closely at the pharmaceutical industry. You see, in addition to patients, clinicians and other stakeholders who should have an avenue to address personal, practical, professional and procedure issues, my view is that it is imperative to have the pharmaceutical i